ArticleCancer research2010
Circulating levels of the innate and humoral immune regulators CD14 and CD23 are associated with adult glioma.
Article in Cancer research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 30 citations in OpenAlex.
- Eosinophil counts as a prognostic marker in glioblastoma: a retrospective cohort study.BMC cancer · 2026Article
- Soluble IgE-binding factors in the serum of food-allergic patients: Possible pathophysiological role of soluble FcεRI as protective factor.Clinical and translational allergy · 2023Article
- Soluble cluster of differentiation 14 levels elevated in bile from gallbladder cancer cases from Shanghai, China.Scientific reports · 2021Article
- Glioblastoma: Is There Any Blood Biomarker with True Clinical Relevance?International journal of molecular sciences · 2020Review
- A Computational Framework for Genome-wide Characterization of the Human Disease Landscape.Cell systems · 2019Article
- An Immune-Related Six-lncRNA Signature to Improve Prognosis Prediction of Glioblastoma Multiforme.Molecular neurobiology · 2018Article
- Identification of blood biomarkers in glioblastoma by SWATH mass spectrometry and quantitative targeted absolute proteomics.PloS one · 2018Article
- Rescuing defective tumor-infiltrating T-cell proliferation in glioblastoma patients.Oncology letters · 2016Article
- Approaching a Scientific Consensus on the Association between Allergies and Glioma Risk: A Report from the Glioma International Case-Control Study.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2016Article
- Circulating biomarkers for gliomas.Nature reviews. Neurology · 2015Review
- Serum macrophage-derived chemokine/CCL22 levels are associated with glioma risk, CD4 T cell lymphopenia and survival time.International journal of cancer · 2015Article
- Interaction of allergy history and antibodies to specific varicella-zoster virus proteins on glioma risk.International journal of cancer · 2014Article
- Antihistamine use and immunoglobulin E levels in glioma risk and prognosis.Cancer epidemiology · 2013Article
- Article
- Immune genes are associated with human glioblastoma pathology and patient survival.BMC medical genomics · 2012Article
- Epidemiology: allergy history, IgE, and cancer.Cancer immunology, immunotherapy : CII · 2012Review
- Arlm1 is a male-specific modifier of astrocytoma resistance on mouse Chr 12.Neuro-oncology · 2012Article
- Eosinophils in glioblastoma biology.Journal of neuroinflammation · 2012Review
- Proteins with altered levels in plasma from glioblastoma patients as revealed by iTRAQ-based quantitative proteomic analysis.PloS one · 2012Article
- Soluble IgE receptors--elements of the IgE network.Immunology letters · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
Allergy history has been consistently inversely associated with glioma risk. Two serologic markers, soluble CD23 (sCD23) and soluble CD14 (sCD14), are part of the innate and adaptive humoral immune systems and modulate allergic responses in opposite directions, with sCD23 enhancing and sCD14 blunting inflammatory responses. We measured sCD23 and sCD14 in serum from blood that was drawn at a single time point from 1,079 glioma patients postdiagnosis and 736 healthy controls. Glioma was strongly associated with high sCD14 [highest versus lowest quartile odds ratio (OR), 3.94; 95% confidence interval (95% CI), 2.98-5.21] and low sCD23 (lowest versus highest quartile OR, 2.5; 95% CI, 1.89-3.23). Results were consistent across glioma histologic types and grades, but were strongest for glioblastoma. Whereas temozolomide treatment was not associated with either sCD14 or sCD23 levels among cases, those taking dexamethasone had somewhat lower sCD23 levels than those not taking dexamethasone. However, sCD23 was associated with case status regardless of dexamethasone treatment. These results augment the long-observed association between allergies and glioma and support a role for the innate and adaptive humoral functions of the immune system, in particular immunoregulatory proteins, in gliomagenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.